此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers

2020年10月9日 更新者:Jiangsu HengRui Medicine Co., Ltd.

Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers (Single Center, Randomized, Open, 3 Cycles, 6 Sequences)

The primary objective of the study is to evaluate the relative bioavailability of three different prescription processes of SHR4640 tablets in healthy volunteers. The secondary objective of the study is to observe the safety of SHR4640 tablets in healthy subjects.

研究概览

地位

未知

干预/治疗

详细说明

Study Type: Interventional Enrollment: Number of Subjects: 24 Type: Anticipated

Allocation : Yes Intervention Model : Single center, randomized, open Intervention Model Description: 3 cycles, 6 sequences Masking: No Masking

Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.

研究类型

介入性

注册 (预期的)

24

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 45年 (成人)

接受健康志愿者

是的

有资格学习的性别

男性

描述

Inclusion Criteria:

  • 1) Voluntarily sign the informed consent form before the start of the activities related to this trial, and be able to understand the procedures and methods of this trial, and be willing to strictly abide by the clinical trial plan to complete this trial; 2) Aged between 18 and 45 years old (including both ends, whichever is the time of signing the informed consent form), male; 3) Body weight ≥ 50 kg, and body mass index (BMI): 19-26 kg/m2 (both ends included).

Exclusion Criteria:

  • Subjects will not be allowed to enter this study if they meet any of the following criteria:

    1. General situation:

    1. Have a fertility plan within 3 months after screening to the last medication, or refuse to use medically approved contraceptive methods;
    2. Drug abusers or drug urine screening positive;
    3. Smokers (average daily smoking 5 or more) or urine Nicotin positive.
    4. The average daily alcohol intake during the first month was more than 25 g (for example, 750 mL beer, 250 mL wine or 50 mL low spirits);
    5. Anyone who had eaten grapefruit or fruit juice products within 2 days before administration, any food or drink containing caffeine (such as coffee, tea, chocolate, cola or other caffeinated carbonated drinks, etc.) and foods or drinks rich in purine food or alcohol.
    6. The researchers judged that the subjects had medical conditions that affected the absorption, distribution, metabolism and excretion of drugs or reduced compliance.

    2. Laboratory tests showed the following conditions:

    1. Those with sUA > 420 µmol / L during the screening period, or those with a previous history of hyperuricemia and / or gout;
    2. Those with estimated glomerular filtration rate (eGFR) < 90 during the screening period;
    3. Those with urolithiasis indicated or suspected by B ultrasound during the screening period;
    4. Those who were positive for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody or syphilis antibody within one month or during the screening period.

    3. There is any history of any of the following or concomitant diseases:

    1. Any clinical history of serious illness or disease or condition that the researchers believe may affect the results of the trial, including, but not limited to, a history of circulatory, endocrine, nervous, digestive, urinary or hematological, immune, mental and metabolic diseases.
    2. People with allergies, including those who are explicitly allergic to research drugs or any ingredient in research drugs, are allergic to any food ingredient or have special requirements for diet, and are unable to follow a uniform diet;
    3. Screening those who have undergone any operation within the first 3 months, or who have not recovered after the operation, or who may have a plan for operation or hospitalization during the trial;
    4. Those who donated blood (or lost blood) within the first 3 months and donated blood (or lost blood) more than 400 mL, or received blood transfusion.

    4. Use any of the following drugs or participate in clinical trials:

    1. Screen people who have participated in clinical trials of any drug or medical device within the previous 3 months;
    2. Take any prescription drug, over-the-counter medicine, Chinese herbal medicine or dietary supplement within 2 weeks before the screening period.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:A
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
实验性的:B
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
实验性的:C
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
实验性的:D
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
实验性的:E
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
实验性的:F
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Cmax
大体时间:Day1 to Day25
Peak plasma concentration
Day1 to Day25
AUC0-t
大体时间:Day1 to Day25
Area under the curve from the time of dosing. Dosing time to the last measurable (positive) concentration.
Day1 to Day25
AUC0-inf(if available)
大体时间:Day1 to Day25
Area under the curve from time 0 to infinity
Day1 to Day25

次要结果测量

结果测量
措施说明
大体时间
Tmax
大体时间:Day1 to Day25
Time of maximum observed concentration
Day1 to Day25
t1/2
大体时间:Day1 to Day25
Half time
Day1 to Day25
CL/F
大体时间:Day1 to Day25
apparent clearance
Day1 to Day25
Vz/F
大体时间:Day1 to Day25
apparent volume of distribution
Day1 to Day25
PD
大体时间:Day1 to Day25
concentration of serum urine acid
Day1 to Day25

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Zourong Ruan, PhD、The Second Affiliated Hospital of Medical College of Zhejiang University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (预期的)

2020年10月1日

初级完成 (预期的)

2020年11月1日

研究完成 (预期的)

2020年12月1日

研究注册日期

首次提交

2020年9月27日

首先提交符合 QC 标准的

2020年10月9日

首次发布 (实际的)

2020年10月14日

研究记录更新

最后更新发布 (实际的)

2020年10月14日

上次提交的符合 QC 标准的更新

2020年10月9日

最后验证

2020年10月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • SHR4640-Ⅰ-109

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅